Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Market Closed - Nasdaq
Other stock markets
 16:00:01 2024-05-02 EDT 		5-day change 1st Jan Change
40.93 USD +4.02% Intraday chart for Celldex Therapeutics, Inc. +12.88% +3.20%
04-17 Sector Update: Health Care Stocks Mixed Wednesday Afternoon MT
04-17 Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering
Sector Update: Health Care Stocks Weaker Monday Afternoon
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates
Sector Update: Health Care Stocks Mixed Premarket Monday
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Celldex Therapeutics Prices $200.5 Million Share Offering
Celldex Shares Rise as Phase 2 Trial Shows Barzolvolimab Meets Primary Efficacy Endpoint for Chronic Spontaneous Urticaria
Sector Update: Health Care Stocks Advance Premarket Monday
Traders Await Next Catalyst as US Equity Futures Edge Higher Pre-Bell
Sector Update: Health Care
Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday
Top Premarket Gainers
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Celldex Therapeutics Says Prurigo Nodularis Phase 1b Study of Barzolvolimab Showed 'Durable Reductions in Itch'
Celldex Therapeutics Q3 Net Loss Widens, Revenue Rises
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. News Celldex Therapeutics, Inc.
  5. Other languages